cancer-screening
(2)
SpotitEarly
SpotitEarly is a healthtech company building an accessible, non-invasive early cancer detection service that combines trained scent-detection beagles with an AI platform to analyze volatile organic compounds (VOCs) in a person's breath. Users collect a breath sample at home and mail it to the company's lab, where beagles screen for cancer-linked odors and SpotitEarly's proprietary LUCID bio-AI platform digitizes and interprets the dogs' behavioral signals. A double-blind clinical study of 1,400 people, published in Nature's Scientific Reports, reported 94% sensitivity and specificity across the four most common cancers - breast, colorectal, lung, and prostate. Founded in Israel and now launching in the U.S., the company aims to make routine multi-cancer pre-screening affordable, at roughly $250 for a single test.
Numen
Numen (formerly Cleancard) is a San Francisco biotech building rapid at-home cancer screens that read like a pregnancy test. By combining synthetic biology, machine learning, and computer vision, its platform detects multiple cancer biomarkers from a single urine sample in about 30 minutes, with no lab machinery required. Founded by Rhodes Scholars Thomas Carroll and Luca Springer, the company's first screens target prostate, bladder, and ovarian cancer, with a mission to drive cancer mortality toward zero.